DK1603915T3 - Substituerede 8-pyridinyl-dihydrospiro-cycloalkyl-pyrimido- 1,2-a-pyrimidin-6-on og 8-pyrimidinyl-dihydrospiro-cycloalkyl-pyrimido-1,2-a-pyrimidin-6-on-derivater og deres anvendelse mod neurogenerative sygdomme - Google Patents

Substituerede 8-pyridinyl-dihydrospiro-cycloalkyl-pyrimido- 1,2-a-pyrimidin-6-on og 8-pyrimidinyl-dihydrospiro-cycloalkyl-pyrimido-1,2-a-pyrimidin-6-on-derivater og deres anvendelse mod neurogenerative sygdomme

Info

Publication number: DK1603915T3
Authority: DK; Denmark
Prior art keywords: dihydrospiro; pyrimido; pyrimidin; cycloalkyl; pyridinyl
Prior art date: 2003-03-07

Application number

DK04717643.3T

Other languages

English (en)

Inventor

Alistair Lochead

Mourad Saady

Franck Slowinski

Philippe Yaiche

Pascal George

Original Assignee

Sanofi Aventis

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-07

Filing date

2004-03-05

Publication date

2010-08-30

2004-03-05 Application filed by Sanofi Aventis, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Aventis

2010-08-30 Application granted granted Critical

2010-08-30 Publication of DK1603915T3 publication Critical patent/DK1603915T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Psychology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK04717643.3T 2003-03-07 2004-03-05 Substituerede 8-pyridinyl-dihydrospiro-cycloalkyl-pyrimido- 1,2-a-pyrimidin-6-on og 8-pyrimidinyl-dihydrospiro-cycloalkyl-pyrimido-1,2-a-pyrimidin-6-on-derivater og deres anvendelse mod neurogenerative sygdomme DK1603915T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03290569A EP1454909B1 (en)	2003-03-07	2003-03-07	8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
PCT/EP2004/003051 WO2004078760A1 (en)	2003-03-07	2004-03-05	SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES

Publications (1)

Publication Number	Publication Date
DK1603915T3 true DK1603915T3 (da)	2010-08-30

Family

ID=32799103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04717643.3T DK1603915T3 (da)	2003-03-07	2004-03-05	Substituerede 8-pyridinyl-dihydrospiro-cycloalkyl-pyrimido- 1,2-a-pyrimidin-6-on og 8-pyrimidinyl-dihydrospiro-cycloalkyl-pyrimido-1,2-a-pyrimidin-6-on-derivater og deres anvendelse mod neurogenerative sygdomme

Country Status (26)

Country	Link
US (2)	US7294632B2 (da)
EP (2)	EP1454909B1 (da)
JP (1)	JP4639182B2 (da)
KR (1)	KR101069984B1 (da)
CN (1)	CN100463908C (da)
AR (1)	AR043485A1 (da)
AT (1)	ATE469153T1 (da)
AU (1)	AU2004218250B2 (da)
BR (1)	BRPI0408189A (da)
CA (1)	CA2516937C (da)
CY (1)	CY1111057T1 (da)
DE (1)	DE602004027354D1 (da)
DK (1)	DK1603915T3 (da)
EA (1)	EA008172B1 (da)
ES (1)	ES2346311T3 (da)
HK (1)	HK1085740A1 (da)
IL (1)	IL170461A (da)
MX (1)	MXPA05009574A (da)
NO (1)	NO20054140L (da)
NZ (1)	NZ542135A (da)
PL (1)	PL1603915T3 (da)
PT (1)	PT1603915E (da)
SI (1)	SI1603915T1 (da)
TW (1)	TWI320785B (da)
WO (1)	WO2004078760A1 (da)
ZA (1)	ZA200507107B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7759353B2 (en)	2005-06-14	2010-07-20	Schering Corporation	Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
US7678363B2 (en)	2005-08-26	2010-03-16	Braincells Inc	Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2377531A2 (en)	2006-05-09	2011-10-19	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP1992621A1 (en)	2007-05-16	2008-11-19	Sanofi-Aventis	Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992625A1 (en) *	2007-05-16	2008-11-19	Sanofi-Aventis	Arylamide pyrimidone compounds
EP1992624A1 (en)	2007-05-16	2008-11-19	Sanofi-Aventis	Heteroarylamide pyrimidone compounds
EP1992620A1 (en)	2007-05-16	2008-11-19	Sanofi-Aventis	Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP2138492A1 (en)	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted pyrimidin-4-one derivatives
EP2138494A1 (en)	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted alkyl pyrimidin-4-one derivatives
EP2138488A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138495A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138493A1 (en)	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted pyrimidone derivatives
EP2138498A1 (en) *	2008-06-26	2009-12-30	sanofi-aventis	Substituted tricyclic derivatives against neurodegenerative diseases
EP2138485A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	Substituted N-Oxide pyrazine derivatives
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CA2766909C (fr)	2009-07-02	2018-06-05	Sanofi	Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one,leur preparation et leur utilisation pharmaceutique
PT2655375E (pt)	2010-12-23	2015-03-02	Sanofi Sa	Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
FR2992316A1 (fr)	2012-06-22	2013-12-27	Sanofi Sa	Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr)	2012-06-22	2015-10-16	Sanofi Sa	Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
US20170165230A1 (en)	2014-04-09	2017-06-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2812636A1 (fr) *	2000-08-02	2002-02-08	Novapharme	Nouveaux derives 2-phenyl imidazo[1.2-a]pyrimidin-5-ones et 2-phenyl 2,3-dihydro imidazo[1,2-a]pyrimidin-5-ones
EA005297B1 (ru) *	2000-09-01	2004-12-30	Санофи-Синтелябо	ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА И 7-ПИРИДИНИЛ-2,3-ДИГИДРОИМИДАЗО[1,2-a]ПИРИМИДИН-5(1H)ОНА
EP1184385A1 (en) *	2000-09-01	2002-03-06	Sanofi-Synthelabo	1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
EP1184383A1 (en) *	2000-09-01	2002-03-06	Sanofi-Synthelabo	9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
ATE401309T1 (de) *	2001-09-21	2008-08-15	Sanofi Aventis	Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen
EP1295885A1 (en) *	2001-09-21	2003-03-26	Sanofi-Synthelabo	Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
EA009456B1 (ru) *	2001-09-21	2007-12-28	Санофи-Авентис	ПРОИЗВОДНЫЕ ПИРИМИДОНА В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ ДЛЯ ПОЛУЧЕНИЯ ИНГИБИТОРОВ GSK3β ИЛИ GSK3β И CDK5/P25
EP1295884A1 (en) *	2001-09-21	2003-03-26	Sanofi-Synthelabo	2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives

2003
- 2003-03-07 EP EP03290569A patent/EP1454909B1/en not_active Expired - Lifetime
2004
- 2004-03-05 AT AT04717643T patent/ATE469153T1/de active
- 2004-03-05 BR BRPI0408189-7A patent/BRPI0408189A/pt not_active IP Right Cessation
- 2004-03-05 ZA ZA200507107A patent/ZA200507107B/en unknown
- 2004-03-05 ES ES04717643T patent/ES2346311T3/es not_active Expired - Lifetime
- 2004-03-05 WO PCT/EP2004/003051 patent/WO2004078760A1/en active Application Filing
- 2004-03-05 TW TW093105914A patent/TWI320785B/zh not_active IP Right Cessation
- 2004-03-05 PT PT04717643T patent/PT1603915E/pt unknown
- 2004-03-05 EA EA200501241A patent/EA008172B1/ru not_active IP Right Cessation
- 2004-03-05 SI SI200431465T patent/SI1603915T1/sl unknown
- 2004-03-05 NZ NZ542135A patent/NZ542135A/en not_active IP Right Cessation
- 2004-03-05 DE DE602004027354T patent/DE602004027354D1/de not_active Expired - Lifetime
- 2004-03-05 JP JP2006504813A patent/JP4639182B2/ja not_active Expired - Fee Related
- 2004-03-05 MX MXPA05009574A patent/MXPA05009574A/es active IP Right Grant
- 2004-03-05 PL PL04717643T patent/PL1603915T3/pl unknown
- 2004-03-05 CA CA2516937A patent/CA2516937C/en not_active Expired - Fee Related
- 2004-03-05 CN CNB2004800109973A patent/CN100463908C/zh not_active Expired - Fee Related
- 2004-03-05 AU AU2004218250A patent/AU2004218250B2/en not_active Ceased
- 2004-03-05 AR ARP040100694A patent/AR043485A1/es not_active Application Discontinuation
- 2004-03-05 DK DK04717643.3T patent/DK1603915T3/da active
- 2004-03-05 EP EP04717643A patent/EP1603915B1/en not_active Expired - Lifetime
2005
- 2005-08-23 IL IL170461A patent/IL170461A/en not_active IP Right Cessation
- 2005-09-06 KR KR1020057016622A patent/KR101069984B1/ko not_active Expired - Lifetime
- 2005-09-06 NO NO20054140A patent/NO20054140L/no not_active Application Discontinuation
- 2005-09-07 US US11/220,999 patent/US7294632B2/en not_active Expired - Fee Related
2006
- 2006-07-14 HK HK06107902.6A patent/HK1085740A1/xx not_active IP Right Cessation
2007
- 2007-10-02 US US11/866,142 patent/US7507743B2/en not_active Expired - Fee Related
2010
- 2010-08-17 CY CY20101100761T patent/CY1111057T1/el unknown

Also Published As

Publication number	Publication date
EP1454909B1 (en)	2008-08-20
ATE469153T1 (de)	2010-06-15
PT1603915E (pt)	2010-07-22
DE602004027354D1 (de)	2010-07-08
ES2346311T3 (es)	2010-10-14
CY1111057T1 (el)	2015-06-11
NO20054140D0 (no)	2005-09-06
IL170461A (en)	2011-11-30
KR101069984B1 (ko)	2011-10-04
JP4639182B2 (ja)	2011-02-23
US20080081819A1 (en)	2008-04-03
EA008172B1 (ru)	2007-04-27
KR20050106500A (ko)	2005-11-09
NZ542135A (en)	2008-06-30
EP1454909A1 (en)	2004-09-08
PL1603915T3 (pl)	2010-10-29
TWI320785B (en)	2010-02-21
MXPA05009574A (es)	2006-05-19
EP1603915A1 (en)	2005-12-14
BRPI0408189A (pt)	2006-03-21
NO20054140L (no)	2005-12-02
JP2006519814A (ja)	2006-08-31
AU2004218250A1 (en)	2004-09-16
HK1085740A1 (en)	2006-09-01
CN100463908C (zh)	2009-02-25
US20060025431A1 (en)	2006-02-02
EP1603915B1 (en)	2010-05-26
ZA200507107B (en)	2006-11-29
CA2516937C (en)	2011-10-25
SI1603915T1 (sl)	2010-08-31
WO2004078760A1 (en)	2004-09-16
AR043485A1 (es)	2005-08-03
CA2516937A1 (en)	2004-09-16
TW200510418A (en)	2005-03-16
AU2004218250B2 (en)	2010-02-25
US7507743B2 (en)	2009-03-24
EA200501241A1 (ru)	2006-04-28
CN1777607A (zh)	2006-05-24
US7294632B2 (en)	2007-11-13

Publication	Publication Date	Title
DK1603915T3 (da)	2010-08-30	Substituerede 8-pyridinyl-dihydrospiro-cycloalkyl-pyrimido- 1,2-a-pyrimidin-6-on og 8-pyrimidinyl-dihydrospiro-cycloalkyl-pyrimido-1,2-a-pyrimidin-6-on-derivater og deres anvendelse mod neurogenerative sygdomme
DK1455785T3 (da)	2009-06-08	Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
NO20053974D0 (no)	2005-08-25	Tienopyrimidinforbindelser og anvendelse derav.
DK1480955T3 (da)	2007-10-29	O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
DK1578755T3 (da)	2007-11-12	Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
NO20024742D0 (no)	2002-10-02	Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20044137L (no)	2004-11-25	Aminoindazolderivater, deres fremstilling og anvendelse samt mellomprodukter
DK1478629T3 (da)	2007-01-29	N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
DK1419150T3 (da)	2005-08-29	1-Phenylsulfonyl-1,3-dihydro-2H-indol-2-on-derivater, deres fremstilling og deres terapeutiske anvendelse
ATE479437T1 (de)	2010-09-15	Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
IS8575A (is)	2006-12-05	3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
DK1537096T3 (da)	2009-02-02	Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
DK1590321T3 (da)	2010-08-09	Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1513836T3 (da)	2006-09-11	Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
NO20043349L (no)	2004-10-05	Kumarinderivater, fremgangsmate for deres framstilling og anvendelse derav
DK1525193T3 (da)	2008-04-28	Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
NO20054135D0 (no)	2005-09-06	Kipolinon/benzoksazin derivater og anvendelser derav
DK1417189T3 (da)	2006-05-08	Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
NL1024677A1 (nl)	2004-05-06	Therapeutische prolinederivaten.
DK1663982T3 (da)	2008-03-17	Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander
DK1773796T3 (da)	2010-06-21	Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
DK1940840T3 (da)	2010-11-22	6-heteroarylpyridoindolon-derivater, fremstilling deraf og terapeutisk anvendelse deraf
NO20052124D0 (no)	2005-04-29	Nye 1,4-diazabisykloalkanderivater, deres fremstilling og anvendelse
DK1753725T3 (da)	2013-05-27	Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.